Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CATALYST PHARMACEUTICALS, INC. (CPRX)
|
Add to portfolio |
|
|
|
| Price: |
$6.92
| | Metrics |
| OS: |
106.6
|
M
| |
|
|
| Market cap: |
$738
|
M
| |
|
|
|
Net cash:
|
$179
|
M
| |
$1.68
|
per share
|
|
EV:
|
$559
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$103
|
M
| |
5.4
|
x EV/EBITDA
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 214.2 | 140.8 | 119.1 | 102.3 | 0.5 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 52.1% | 18.3% | 16.4% | 20361.2% | | | | |
| Cost of goods sold | 34.4 | 21.9 | 17.0 | 14.8 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 179.8 | 118.9 | 102.0 | 87.5 | 0.5 | 0.0 | 0.0 | 0.0 |
| Gross margin | 83.9% | 84.5% | 85.7% | 85.6% | 100.0% | | | |
| Selling, general and administrative | 58.2 | 49.6 | 44.2 | 36.9 | 15.9 | | | |
| Research and development | 19.8 | 16.9 | 16.5 | 18.8 | 19.9 | 11.4 | 11.4 | 11.8 |
| General and administrative | | | | | | 7.3 | 7.9 | 8.6 |
| EBITA | 102.9 | 52.4 | 41.3 | 31.8 | -35.3 | -18.7 | -19.3 | -20.4 |
| EBITA margin | 48.1% | 37.2% | 34.7% | 31.1% | -7059.0% | | | |
| Amortization of intangibles | 1.1 | | | | | | | |
| EBIT | 101.8 | 52.4 | 41.3 | 31.8 | -35.3 | -18.7 | -19.3 | -20.4 |
| EBIT margin | 47.5% | 37.2% | 34.7% | 31.1% | -7059.0% | | | |
| Pre-tax income | 104.7 | 52.7 | 41.9 | 33.4 | -34.0 | -18.4 | -18.1 | -20.2 |
| Income taxes | 21.6 | 13.2 | -33.1 | 1.5 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 20.7% | 25.0% | | 4.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 83.1 | 39.5 | 75.0 | 31.9 | -34.0 | -18.4 | -18.1 | -20.2 |
| Net margin | 38.8% | 28.0% | 63.0% | 31.2% | -6800.7% | | | |
| |
| Diluted EPS | $0.75 | $0.37 | $0.71 | $0.30 | ($0.33) | ($0.21) | ($0.22) | ($0.25) |
| Shares outstanding (diluted) | 111.4 | 107.8 | 106.2 | 106.0 | 102.6 | 85.8 | 82.9 | 80.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|